Severity

A subset of Member States and areas monitor severe disease related to influenza virus infection by surveillance of 1) hospitalized laboratory-confirmed influenza cases in ICUs (11 Member States and areas) or other wards (7 Member States and areas), or 2) severe acute respiratory infection (SARI; 17 Member States and areas, mostly located in the eastern part of the Region).

1.1) Hospitalized laboratory-confirmed influenza cases – ICUs

There were no reports of hospitalized laboratory-confirmed influenza in ICUs for weeks 26-30/2020.

1.2) Hospitalized laboratory-confirmed influenza cases – other wards

There were no reports of laboratory-confirmed influenza in wards other than ICUs for weeks 26-30/2020.

2. SARI surveillance

For week 30/2020, 62 SARI cases were reported by 3 Member States. None of the 58 specimens tested for influenza virus were positive.

Of the SARI cases tested for influenza viruses in weeks 21-30/2020, 1 tested positive. It was influenza type B.  

Of 2 966 SARI cases reported in weeks 21-30/2020, 2 965 had a recorded age and, of these, 45% were 15–64 years old and 31% were 0-4 years old.

Mortality monitoring

Pooled estimates of all-cause mortality for the countries participating in the EuroMOMO network have reached normal levels, following a period of substantial excess mortality observed in some countries, coinciding with the COVID-19 pandemic. However, in some countries there might be a tendency towards an increase in mortality, possibly due to heat waves.